|
|
News Breaks | | | | March 18, 2013 | | 05:55 EDT |  | CBST, CBST, CBST, AMGN, AMGN, AMGN, ABT, ABT, ABT, BIIB, BIIB, BIIB, MRK, MRK, MRK, LLY, LLY, LLY | FDA News to hold a summit
Biopharmaceutical Good Distribution Practices Summit is being held in Bethesda, Maryland on March 18-20. | |
|
News For CBST;AMGN;ABT;BIIB;MRK;LLY From The Last 14 Days Check below for free stories on CBST;AMGN;ABT;BIIB;MRK;LLY the last two weeks. |
|
|
| May 17, 2013 | | 05:51 EDT |  | CBST | Stocks with implied volatility movement; CBST CELG
 Subscribe for More Information | | | May 16, 2013 | | 08:55 EDT | | LLY, MRK | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information | | | 07:29 EDT | | BIIB, CBST | Leerink to host a bus tour
Boston Biopharma Bus Tour travels throughout Boston on May 16-17. | | | May 15, 2013 | | 17:46 EDT |  | CBST | SAC Capital gives quarterly update on stakes
NEW STAKES: Discovery (DISCA), Liberty Global (LBTYA), Liberty Media (LMCA), Norwegian Cruise Line (NCLH), and Cubist (CBST). INCREASED STAKES: Suncor (SU), EQT Corporation (EQT), Amazon.com (AMZN), Visa (V), and GNC Holdings (GNC). DECREASED STAKES: News Corp. (NWSA), Facebook (FB), Sherwin-Williams (SHW), and Avago (AVGO). LIQUIDATED STAKES: Coach (COH), Dover (DOV), and Virgin Media (VMED), . | | | 16:00 EDT | | CBST | Optimer calls active following takeover report
Optimer (OPTR) May and June 17 calls are active on 5,600 contracts (500 puts) according to Track Data. Traders are taking positions for large price movement on Cubist (CBST) offered to buy the company for $20 per share, Reuters says. | | | 15:54 EDT | | CBST | Optimer up 12.5%, to $16.03 after Reuters report Cubist offered $20 per share
Subscribe for More Information | | | 15:53 EDT | | CBST | Cubist offered to buy Optimer for $20 per share, Reuters says
Subscribe for More Information | | | May 14, 2013 | | 17:39 EDT | | MRK | Moody's lowers Merck's guaranteed debt to A1 from Aa3; stable outlook
Moody's Investors Service lowered the long-term ratings of Merck by one notch, including the guaranteed senior unsecured rating to A1 from Aa3 and the non-guaranteed senior unsecured rating to A2 from A1. This action concludes a review for downgrade initiated on May 1, 2013. At the same time, Moody's affirmed Merck's Prime-1 commercial paper rating. The rating outlook is stable. | | | 15:09 EDT | | BIIB | Biogen has a conference call hosted by JPMorgan
JPMorgan Analysts Meacham and Kasimov host a conference call with CEO George Scangos and CFO Paul Clancy on May 17 at 10 am. | | | 09:09 EDT | | LLY | Eli Lilly announces CEO John Lechleiter recovering from surgery
Subscribe for More Information | | | | 07:24 EDT | | LLY | EBD Group to host a conference
BioTrinity 2013 is being held in Newbury, England on May 14-16. | | | May 13, 2013 | | 16:53 EDT |  | CBST | Optimer gets bids from AstraZeneca, Cubist, Astellas, Bloomberg says
Optimer (OPTR) has received first round bids from AstraZeneca (AZN), Cubist (CBST), and Astellas, reports Bloomberg, citing people familiar with the matter. Shares of Optimer spiked higher following the report, closing up $1.85, or 14.44%, to $14.66. The report notes the company disclosed almost three months ago it was exploring its strategic options. Reference Link | | | 15:55 EDT | | CBST | Optimer gets first round bids from AstraZeneca, Cubist, Bloomberg says
Subscribe for More Information | | | 11:12 EDT |  | BIIB | Biogen MS drug scripts grew 38% week-over-week, says Leerink
Subscribe for More Information | | | 08:55 EDT | | AMGN | Biosimiliar drug bill to be taken up in Senate, LA Times reports
Subscribe for More Information | | | 07:34 EDT | | BIIB | Biogen says FDA accepts BLA for Eloctate
Subscribe for More Information | | | May 10, 2013 | | 11:48 EDT | | LLY, MRK | Drugmakers to face pressure on U.S. prices, Reuters says
Subscribe for More Information | | | 08:02 EDT | | LLY | Eli Lilly's Enzastaurin Phase III study did not meet primary endpoint
Eli Lilly announced Phase III clinical trial results from enzastaurin's PRELUDE study, which explored the molecule as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma. The study failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of relapse following rituximab-based chemotherapy. There were no new safety findings, and the safety data were consistent with previously disclosed studies. Lilly will stop development of enzastaurin, which is expected to result in a second-quarter charge to R&D expense of approximately $30M. The company's previously-issued financial guidance for 2013 remains unchanged. | | | 08:00 EDT | | BIIB | Biogen should be bought on weakness before Q2 Tecfidera data, says Stifel
Stifel recommends buying Biogen on any weakness before the company reports Q2 Tecfidera sales data. The firm thinks that any continued strength in Tecfidera prescription data will cause analysts to revise their estimates higher, and it keeps a Buy rating on the shares. | | | 06:53 EDT | | MRK | GlaxoSmithKline, Merck to discount cancer vaccine in poor nations, NY Times says
Subscribe for More Information | | |
|
|
|
|
|
|
